JP2007529196A5 - - Google Patents

Download PDF

Info

Publication number
JP2007529196A5
JP2007529196A5 JP2006526599A JP2006526599A JP2007529196A5 JP 2007529196 A5 JP2007529196 A5 JP 2007529196A5 JP 2006526599 A JP2006526599 A JP 2006526599A JP 2006526599 A JP2006526599 A JP 2006526599A JP 2007529196 A5 JP2007529196 A5 JP 2007529196A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
binding molecule
ser
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006526599A
Other languages
English (en)
Japanese (ja)
Other versions
JP4762142B2 (ja
JP2007529196A (ja
Filing date
Publication date
Priority claimed from US10/666,332 external-priority patent/US20050069538A1/en
Priority claimed from GB0414309A external-priority patent/GB0414309D0/en
Application filed filed Critical
Priority claimed from PCT/EP2004/010471 external-priority patent/WO2005026210A2/en
Publication of JP2007529196A publication Critical patent/JP2007529196A/ja
Publication of JP2007529196A5 publication Critical patent/JP2007529196A5/ja
Application granted granted Critical
Publication of JP4762142B2 publication Critical patent/JP4762142B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006526599A 2003-09-18 2004-09-17 治療用結合分子 Expired - Fee Related JP4762142B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/666,332 US20050069538A1 (en) 2003-09-18 2003-09-18 Therapeutic binding molecules
US10/666,332 2003-09-18
GB0414309A GB0414309D0 (en) 2004-06-25 2004-06-25 Organic compounds
GB0414309.5 2004-06-25
PCT/EP2004/010471 WO2005026210A2 (en) 2003-09-18 2004-09-17 Therapeutic binding molecules

Publications (3)

Publication Number Publication Date
JP2007529196A JP2007529196A (ja) 2007-10-25
JP2007529196A5 true JP2007529196A5 (enExample) 2008-04-17
JP4762142B2 JP4762142B2 (ja) 2011-08-31

Family

ID=34315457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526599A Expired - Fee Related JP4762142B2 (ja) 2003-09-18 2004-09-17 治療用結合分子

Country Status (28)

Country Link
EP (1) EP1664122B1 (enExample)
JP (1) JP4762142B2 (enExample)
KR (1) KR20060079232A (enExample)
AR (2) AR045765A1 (enExample)
AT (1) ATE461219T1 (enExample)
AU (1) AU2004272289B2 (enExample)
BR (1) BRPI0414515A (enExample)
CA (1) CA2537217A1 (enExample)
CY (1) CY1110033T1 (enExample)
DE (1) DE602004026081D1 (enExample)
DK (1) DK1664122T3 (enExample)
EC (1) ECSP066432A (enExample)
ES (1) ES2341341T3 (enExample)
HR (1) HRP20100334T1 (enExample)
IL (1) IL173820A0 (enExample)
IS (1) IS8397A (enExample)
MA (1) MA28041A1 (enExample)
MY (1) MY143963A (enExample)
NO (1) NO20061681L (enExample)
NZ (1) NZ545605A (enExample)
PE (1) PE20060019A1 (enExample)
PL (1) PL1664122T3 (enExample)
PT (1) PT1664122E (enExample)
RU (1) RU2386639C2 (enExample)
SI (1) SI1664122T1 (enExample)
TN (1) TNSN06087A1 (enExample)
TW (1) TW200521231A (enExample)
WO (1) WO2005026210A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
TWI579722B (zh) * 2015-02-17 2017-04-21 陳沛隆 藥物不良反應風險評估方法及其裝置
WO2016164502A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
JP2019522050A (ja) * 2016-06-17 2019-08-08 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 細胞の枯渇のための組成物および方法
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR20200094181A (ko) 2017-11-29 2020-08-06 마젠타 테라퓨틱스 인코포레이티드 Cd5+ 세포를 고갈시키기 위한 조성물 및 방법
WO2022020583A1 (en) * 2020-07-24 2022-01-27 The Board Of Trustees Of The Leland Standford Junior University Compositions and methods for modulation of sirpalpha-mediated signaling
WO2022079199A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス,インコーポレイテッド プロテアーゼ活性化cd45ゲートcar
US20250041339A1 (en) 2021-11-19 2025-02-06 The Trustees Of The University Of Pennsylvania Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG67924A1 (en) * 1991-07-25 1999-10-19 Idec Pharma Corp Recombinant antibodies for human therapy
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2007529196A5 (enExample)
AU2009245354C1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
ES2744526T3 (es) Anticuerpos anti-MCAM y métodos de uso asociados
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
JP2020504171A (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
JP7257971B2 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
WO2014089209A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
CN111138540A (zh) 治疗自身免疫疾病的结合fcrn的抗体
MX2012011629A (es) Proteinas de union a tnf-alfa.
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
RU2003126168A (ru) Терапевтические связывающие молекулы
RU2006112598A (ru) Связывающие молекулы, обладающие терапевтической активностью
CN105745225A (zh) Nav1.7抗体和使用所述抗体的方法
CN116249717A (zh) 识别分拣蛋白的抗体
TW202134286A (zh) 抗gpc3抗體、其抗原結合片段及其醫藥用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
JP7366353B2 (ja) 抗インドキシル硫酸の単離されたモノクローナル抗体及び/又はその抗原結合断片の組成物及びその用途
CA3242070A1 (en) Antibodies recognizing sortilin
JP2024523514A (ja) 抗cd40抗体、その抗原結合断片及び医薬用途
US20200131263A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2025014712A2 (en) Antibodies against cd14 and uses thereof
CN114761042A (zh) Il-38特异性抗体
WO2019109974A1 (zh) 抗pd-l1抗体及其抗原结合片段
RU2795411C2 (ru) Моноклональные антитела к интерлейкину-31 для ветеринарного применения
JP2022523750A (ja) 抗-fgf19抗体